Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Robert Wang, MD
Advertisement
Articles by Robert Wang, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5